Novadaq Technologies Inc. (NASDAQ:NVDQ) has been given a consensus rating of “Hold” by the eleven brokerages that are covering the stock, American Banking and Market News reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and five have given a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $16.14. Novadaq Technologies Inc. (NASDAQ:NVDQ) shares after opening at $24.09 moved to $24.09 on last trade day and at the end of the day closed at $20.81. Company price to sales ratio in past twelve months was calculated as 32.62. Novadaq Technologies Inc. (NASDAQ:NVDQ) showed a negative weekly performance of -3.97%.
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) announced the pricing of an underwritten public offering of 2,857,143 shares of its common stock to institutional and other investors at a price to the public of $3.50 per share. In connection with the offering, Cyclacel has granted the underwriters a 30-day option to purchase up to an additional 428,571 shares of common stock to cover over-allotments, if any. All of the shares of common stock in this offering are to be sold by Cyclacel. Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) shares advanced 2.16% in last trading session and ended the day on $3.97. CYCC return on equity ratio is recorded as -161.80% and its return on assets is -115.30%. Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) yearly performance is -26.41%.
Sorrento Therapeutics, Inc. (NASDAQ:SRNE), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, announced that it will present data on the comparison of Cynviloq and Abraxane (nab-paclitaxel) pharmacokinetics (PK) from animal studies. Sorrento Therapeutics Inc (NASDAQ:SRNE) shares moved down -10.14% in last trading session and was closed at $11.26, while trading in range of $10.70 – 12.53. Sorrento Therapeutics Inc (NASDAQ:SRNE) year to date (YTD) performance is 39.01%.
Analysts at Jefferies Group upped their price target on shares of Orthofix International N.V. (NASDAQ:OFIX) from $34.00 to $36.00 in a research report issued to clients and investors on Tuesday, AR Network reports. Jefferies Group’s price target points to a potential upside of 12.46% from the stock’s previous close. Orthofix International NV (NASDAQ:OFIX) weekly performance is 9.54%. On last trading day company shares ended up $57. Orthofix International NV (NASDAQ:OFIX) distance from 50-day simple moving average (SMA50) is 40.58%. Analysts mean target price for the company is $31.50.